Detalles de la búsqueda
1.
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Rheumatology (Oxford)
; 59(11): 3303-3313, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32277824
2.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Lancet
; 391(10139): 2513-2524, 2018 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29908670
3.
Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
Rheumatology (Oxford)
; 55(8): 1458-65, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114561
4.
Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
Arthritis Res Ther
; 23(1): 9, 2021 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33407801
5.
Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.
Int J Rheum Dis
; 24(12): 1530-1539, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779576
6.
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
Arthritis Res Ther
; 21(1): 263, 2019 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31791386
7.
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Arthritis Rheumatol
; 68(12): 2857-2866, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27390150
Resultados
1 -
7
de 7
1
Próxima >
>>